biotech
Adrienne G. Waks
Sponsor view across the ADC target screen, including linked targets and source-linked trial evidence.
ADC target activity
Tracked targets
| Target | Trial count | Evidence |
|---|---|---|
| HER2 / ERBB2 | 1 | Source |
Linked trials
Clinical evidence links
- NCT06100874: A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) (ACTIVE_NOT_RECRUITING)